Provided By GlobeNewswire
Last update: May 14, 2025
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial
Read more at globenewswire.comNASDAQ:APRE (7/3/2025, 8:28:02 PM)
1.74
+0.04 (+2.35%)
Find more stocks in the Stock Screener